Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine

PURPOSE: HER2+ breast cancer patients benefit from trastuzumab-containing regimens with improved survival. Adaptive immunity, including cytotoxic T cell and antibody immunity, is critical to clinical efficacy of trastuzumab. Since helper T cells are central to the activation of these antitumor effec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Knutson, Keith L., Block, Matthew S., Norton, Nadine, Erskine, Courtney L., Hobday, Timothy J., Dietz, Allan B., Padley, Douglas J., Gustafson, Michael P., Puglisi-Knutson, Danell J., Mangskau, Toni K., Chumsri, Saranya, Dueck, Amylou C., Karyampudi, Lavakumar, Wilson, Glynn, Degnim, Amy
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056565/
https://ncbi.nlm.nih.gov/pubmed/31757875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2123
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars